Range Low Price High Price Comment
30 days $0.470 $0.470 Thursday, 17th Aug 2023 CYAD stock ended at $0.470. During the day the stock fluctuated 0% from a day low at $0.470 to a day high of $0.470.
90 days $0.470 $0.470
52 weeks $0.460 $3.07

Historical Celyad SA prices

Date Open High Low Close Volume
2023-07-13 $0.470 $0.470 $0.470 $0.470 0
2023-07-12 $0.470 $0.470 $0.470 $0.470 0
2023-07-11 $0.470 $0.470 $0.470 $0.470 0
2023-07-10 $0.470 $0.470 $0.470 $0.470 0
2023-07-07 $0.470 $0.470 $0.470 $0.470 0
2023-07-06 $0.470 $0.470 $0.470 $0.470 0
2023-07-05 $0.470 $0.470 $0.470 $0.470 0
2023-07-03 $0.470 $0.470 $0.470 $0.470 0
2023-06-30 $0.470 $0.470 $0.470 $0.470 0
2023-06-29 $0.470 $0.470 $0.470 $0.470 0
2023-06-28 $0.470 $0.470 $0.470 $0.470 0
2023-06-27 $0.470 $0.470 $0.470 $0.470 0
2023-06-26 $0.470 $0.470 $0.470 $0.470 0
2023-06-23 $0.470 $0.470 $0.470 $0.470 0
2023-06-22 $0.470 $0.470 $0.470 $0.470 0
2023-06-21 $0.470 $0.470 $0.470 $0.470 0
2023-06-20 $0.470 $0.470 $0.470 $0.470 0
2023-06-16 $0.470 $0.470 $0.470 $0.470 0
2023-06-15 $0.470 $0.470 $0.470 $0.470 0
2023-06-14 $0.470 $0.470 $0.470 $0.470 0
2023-06-13 $0.470 $0.470 $0.470 $0.470 0
2023-06-12 $0.470 $0.470 $0.470 $0.470 0
2023-06-09 $0.470 $0.470 $0.470 $0.470 0
2023-06-08 $0.470 $0.470 $0.470 $0.470 0
2023-06-07 $0.470 $0.470 $0.470 $0.470 0
Click to get the best stock tips daily for free!

About Celyad SA

Celyad SA Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical... CYAD Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT